Brief: Stayble Therapeutics Q4 Oper Loss To SEK 1.5 Mln
25/02/2026 07:47
Feb 25 (Reuters) - Stayble Therapeutics AB STABL.ST: Q4 OPERATING PROFIT (EBIT) AMOUNTED TO KSEK -1,541 Q4 LOSS FOR THE PERIOD AMOUNTED TO KSEK -1,525 (-3,013) Source text: ID:nWkr3K6cNP Further company coverage: STABL.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Stayble Therapeutics AB
See all newsBrief: Stayble Therapeutics Delisted From Nasdaq First North Growth Market
Brief: Stayble Therapeutics To Apply For Bankruptcy
Brief: Stayble Therapeutics Q1 EBIT Loss Narrows To SEK 6.9 Mln
Brief: Stayble Therapeutics Enters Into LoI On Potential Strategic Collaboration, Financing
Brief: Stayble Therapeutics Q4 Oper Loss To SEK 1.5 Mln